BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BioNTech SE

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026

$89.21+1.50 (+1.71%)

Close on Oct 19, 2026

BioNTech SE income statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	2,870	2,751	3,819	17,311	18,977	482	109	128	62
Cost of Revenue	642	541	600	2,995	2,912	59	17	14	9.32
Gross Profit	2,228	2,210	3,219	14,316	16,065	423	91	114	52
Research & Development	2,105	2,254	1,783	1,537	949	645	227	143	85
Selling & Marketing	110	68	63	60	50	15	2.70	3.04	6.60
Operating Income	-1,405	-1,314	690	12,643	15,284	-82	-182	-54	-61
Interest Expense	70	27	24	19	305	65	2.00	0.05	26
Interest & Investment Income	424	664	520	330	68	1.60	4.10	8.05	2.13
Income from Equity Investments	–	–	–	–	–	–	–	-0.08	-0.08
Asset Impairment Charges	72	–	–	–	–	–	–	–	–
Pretax Income	-1,051	-678	1,186	12,954	15,046	-146	-179	-48	-86
Income Tax Expense	85	-12	256	3,520	4,754	-161	-0.20	0.60	0.05
Net Income incl. Noncontrolling Interests	-1,136	-665	930	9,434	10,293	15	-179	-48	-86
Minority Interest in Earnings	–	–	–	–	0	0	-0.10	-0.24	-0.30
Net Income	-1,136	-665	930	9,434	10,293	15	-179	-48	-86
EPS (Basic)(per share)	-4.70	-2.77	3.87	38.78	42.18	0.06	-0.85	-0.25	-0.51
EPS (Diluted)(per share)	-4.70	-2.77	3.83	37.77	39.63	0.06	-0.85	-0.25	-0.51
Shares Outstanding (Basic, Weighted)(shares)	242	240	241	243	244	235	212	191	167
Shares Outstanding (Diluted, Weighted)(shares)	242	240	243	250	260	249	212	191	167
EBITDA	-1,022	-1,016	874	12,766	15,359	-44	-148	-32	-51

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 77.6%
Operating margin: -49.0%
Net margin: -39.6%
Return on equity, FY2025: –

Financial strength

Current ratio: 7.54
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 358.3%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.